Expand MBX Menu
MBX MENU

MBX Latest Press Releases

-- September 9, 2026 --

MBX Biosciences to Participate in Upcoming Investor Conferences Globe Newswire 8:00 AM

-- September 8, 2026 --

MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer Globe Newswire 8:00 AM

-- August 27, 2026 --

MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism Globe Newswire 8:00 AM

-- August 6, 2026 --

MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights Globe Newswire 8:00 AM

-- July 15, 2026 --

Attovia Therapeutics Appoints John W. Smither to Board of Directors Globe Newswire 8:30 AM

-- July 13, 2026 --

MBX Biosciences Announces Executive Leadership Transition to Support the Company's Next Phase of Growth Globe Newswire 4:15 PM

-- June 12, 2026 --

MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism Globe Newswire 7:00 AM

-- June 1, 2026 --

MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026 Globe Newswire 8:00 AM

-- May 26, 2026 --

MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City Globe Newswire 8:00 AM

-- May 11, 2026 --

MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing Globe Newswire 7:00 AM

-- May 7, 2026 --

MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights Globe Newswire 8:00 AM
MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award Globe Newswire 7:00 AM
Market Data Delayed 15 Minutes